Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus, a product-oriented biopharmaceutical company, has signed a new drug delivery technology evaluation contract with a US-based biotech company.
Subscribe to our email newsletter
Under the terms of the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’s proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
OctoPlus said that it’s strategy will increasingly focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. Currently, OctoPlus is working on five projects to develop a controlled release formulation for a client.